Incyte rises after beating quarterly results estimates

Shares of Incyte INCY.O rise 3% to $61.33 premarket

Drugmaker's Q1 adj. EPS of $1.16 beats estimates of $1.02 - LSEG data

Its Q1 revenue of $1.05 bln comes above estimates of $993.1 mln

Co expects annual sales of key drug Jakafi to be between $2.95 bln and $3 bln, up from prior range of $2.93 bln to $2.98 bln

Up to last close, stock had fallen 13.8% YTD